SIASUN(SZ:300024) Sou Hu Cai Jing·2025-12-31 02:02Core Insights - Weijing Medical has completed a B+ round financing of over 100 million yuan, with exclusive investment from Guotai Junan Innovation Investment Co., Ltd. and additional investment from strategic shareholder Kangji Medical [2][3] Funding Utilization - The raised funds will primarily accelerate the commercialization of products and promote the research and clinical registration of next-generation products [3] Technological Advancements - Weijing Medical has developed a competitive product matrix addressing clinical pain points in surgery, achieving significant breakthroughs in technology [4] - Optimization of control systems has led to lightweight and smooth operations, addressing core challenges in motion compensation and gap control [4] - System performance has improved with overall latency controlled within 80 milliseconds, and video systems achieving 4K fluorescence signal capture and transmission within 40 milliseconds [4] - The surgical experience has been enhanced with dual 4K display and image transmission latency below 55 milliseconds, providing immersive high-definition surgical vision [4] Innovation in Surgical Navigation - The company is focusing on embodied intelligence, particularly in remote surgery and AI navigation, developing innovative solutions that meet clinical needs [4] - The intraoperative navigation system can identify and alert surgeons to key anatomical structures, aiding in precise surgical planning and enhancing safety and operational accuracy [4] Product Registration and Clinical Application - Weijing Medical's core product, the four-arm laparoscopic surgical robot, received its registration certificate in April 2025, marking a new phase for domestic surgical robots in large-scale clinical applications [5] - The Weijing robot is currently in trial use at over 10 top hospitals across China, including Peking University Third Hospital and Shanghai Changzheng Hospital [5]